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It is generally agreed that estrogens, and possibly androgens, are important in the etiology of
breast cancer, but no consensus exists as to the precise estrogenic or androgenic environment
that characterizes risk, or the exogenous factors that influence the hormonal milieu. Nearly all the
epidemiological studies conducted in the 1970s and 1980s were hospital-based case-control
studies in which specimen sampling was performed well after the clinical appearance of the
disease. Early prospective cohort studies also had limitations in their small sample sizes or short
follow-up periods. However, more recent case-control studies nested within large cohorts, such
as the New York University Women's Health Study and the Ormoni e Dieta nell'Eziologia dei
Tumori study in Italy, are generating new data indicating that increased levels of estrone, estradiol
and bioavailable estradiol, as well as their androgenic precursors, may be associated with a 4- to
6-fold increase in the risk of postmenopausal breast cancer. Further new evidence, which
complements and expands the observations from the latter studies, shows that women with the
thickest bone density, which may be a surrogate for cumulated exposure to hormones,
experience severalfold increased risk of subsequent breast cancer as compared to women with
thin bones. These data suggests that endogenous sex hormones are a key factor in the etiology
of postmenopausal breast cancer. New prospective cohort studies should be conducted to
examine the role of endogenous sex hormones in blood and urine samples obtained early in the
natural history of breast cancer jointly with an assessment of bone density and of other important
risk factors, such as mammographic density, physical activity, body weight, and markers of
individual susceptibility, which may confer increased risk through an effect on the metabolism
of endogenous hormones or through specific metabolic responses to Western lifestyle and diet.
Environ Health Perspect 105(Suppl 3):587-592 (1997)
Key words: breast neoplasms, estrogens, estrone, estradiol, sex hormone-binding globulin
Endogenous Estrogens
and Breast Cancer Risk
Because of their physiologic stimulatory
actions on mammary glands, estrogens,
especially estrone and estradiol, have long
been linked to the promotion and growth
of breast cancer (1). Animal studies have
shown repeatedly that estrogens are able to
induce and promote mammary tumors and
that the removal of the ovaries, or the
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administration of antiestrogenic drugs,
achieves the opposite effect (2,3). Sub-
stantial indirect evidence (4,5) supports an
etiologic role for estrogens in human breast
cancer. For example, it has long been
known that reproductive factors, such as
delayed age at first full-term birth, increase
a woman's risk for breast cancer, and that
bilateral oophorectomy at a young age
confers lasting protection against breast
cancer (6). The hormonal environment
typical of premenopausal women, charac-
terized by high levels of estradiol, proges-
terone, and gonadotropins, has been
suggested (7) as the key to understanding
why, in all populations, the incidence of
breast cancer increases much more steeply
among premenopausal women than among
postmenopausal women (8,9).
Epidemiological research seeking direct
evidence on the role ofendogenous estro-
gens in breast cancer has produced con-
flicting and disappointing results (10). In
the late 1960s and 1970s, a number of
hospital-based case-control studies of the
relationship between urinary and circulat-
ing estrogens and breast cancer (11-17)
generated enthusiasm and were followed by
a wave ofsimilar efforts (7), most notably
at the Harvard School of Public Health
(12,18-21). Such efforts produced incon-
sistent results. Most reports found no asso-
ciation (22-24), although quite a few
observed a modest, positive relationship
with estradiol (13,21,25-30).
Renewed expectations followed the
1981 publication ofa report by Siiteri and
colleagues (31) suggesting that only the
free and albumin-bound fractions of estra-
diol, rather that the fraction bound to sex
hormone-binding globulin (SHBG), are
relevant to breast cancer. The hypothesis
was based on observations that 35 to 65%
ofestradiol and 50 to 75% of testosterone
circulate bind to SHBG (a glycoprotein
secreted by the liver), from which they dis-
sociate very slowly (32). Approximately 0.5
to 2% of the steroids circulate unbound
(free) and the rest bind to albumin. The
prevailing opinion concerning the role of
SHBG is that binding reduces the avail-
ability ofestradiol to the cells and that the
free hormone (including the fraction that
continuously dissociates from binding with
albumin) diffuses freely into the cytoplasm
and thus is immediately available for
biologic action (33).
Siiteri's initial paper (31) reporting
that free estradiol was elevated in post-
menopausal breast cancer was followed by
a number of similar case-control studies
(21,26,30,34-42). With some exceptions,
(36,39,42) these studies appeared to
confirm Siiteri's initial observations, but
their overall impact was modest when it
became evident that the observed associa-
tion was not of sufficient strength to
explain much of breast cancer epidemiol-
ogy. Enthusiasm for the hypothesis was
further dampened by a number of
case-control studies of SHBG, some
reporting weaker than predicted protective
associations (34,40,43,44), and many fail-
ing to observe any (21,29,30,39,42,45).
To date, only a handful ofinvestigators
have examined the role of endogenous
estrogens prospectively. In the mid-1950s,
Bulbrook and colleagues (46) pioneered
the effort by initiating a prospective cohort
study of 5000 women in the British island
of Guernsey, which eventually led to the
identification of 27 cases of breast cancer.
Initially, they reported no differences in
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urinary estrogens between cases and
noncases, but later showed that serum
levels of free estradiol were considerably
higher among the cases than the controls
in the same population (38). More
recently, Wysowski and colleagues (47)
conducted a case-control study nested in a
prospective cohort study of 11,009 women
in Washington County, Maryland, which
was assembled in 1974 (48). In a small
study group that included 17 premeno-
pausal and 39 postmenopausal cases, they
reported no change in breast cancer risk
associated with serum levels of estrone,
total estradiol, estriol, and progesterone
among premenopausal and postmeno-
pausal subjects. These results were later
questioned on technical grounds (49).
Later a small prospective cohort study in
California (the Rancho Bernardo study)
reported no association between breast
cancer and serum levels of estrone, estra-
diol, and SHBG in 442 middle-age
women, with 15 postmenopausal breast
cancer cases (50).
The current chapter ofthe epidemiology
ofbreast cancer concerned with the role of
reproductive hormones could have ended
in the early 1990s with the conclusion that,
contrary to expectations, endogenous
estrogens measured in blood and urine do
not reflect breast cancer risk. Moreover,
because epidemiologic evidence did not
suggest evident associations, launching new
epidemiologic studies on the topic would
have appeared futile, or even wasteful.
Despite the lack ofsupporting evidence,
a few additional studies, which had been
designed specifically to address the role of
endogenous hormones in breast cancer,
were already underway. The results offour
of these studies were published in rapid
sequence between late 1994 and early
1996. First, a new case-control study,
nested in the Washington County cohort
and based on a set of 10 to 12 pre-
menopausal and 29 postmenopausal cases
who had not been part ofprevious analy-
ses, reported a 4-fold increase in breast
cancer risk associated with upper-tertile
total and free estradiol levels in the post-
menopausal group (51). Subsequently, the
preliminary results of a cohort of more
than 14,000 women in New York (the
New York University Women's Health
Study), which had been assembled and fol-
lowed up since 1985, were reported (52).
In a postmenopausal case-control study
nested within this cohort (130 cases, 271
controls), estrone, total estradiol, and free
estradiol were related to a 3- to 6-fold
increase in breast cancer risk amongwomen
who were sampled 2 years or more before
cancer diagnosis; SHBG, as estimated by
the percentage of estradiol bound to the
protein, appeared strongly protective
(53). Soon afterward, Berrino and col-
leagues (54) reported the results of a
prospective cohort study in northern Italy
(the Ormoni e Dieta nell'Eziologia dei
Tumori study), with a design similar to
the New York Women's Health Study
Cohort. In a case-control study nested in
this cohort of 10,000 (24 breast cancer
cases out of 4040 postmenopausal sub-
jects), they reported a 5.5-fold increase in
breast cancer risk in the upper tertile of
serum estradiol, as well as a strong protec-
tive effect of SHBG, and a strong associa-
tion with serum testosterone. Dorgan et al.
(55) reported the result of a case-control
study (71 cases, 133 controls) nested
within the Columbia, Missouri, Breast
Cancer Serum Bank, a cohort of 3375
postmenopausal women enrolled between
1977 and 1989. In this study, women in
the highest quartile ofbioavailable (non-
SHBG bound) estradiol and testosterone
had a 5- to 6-fold increase in risk ofbreast
cancer. Key and colleagues recently
reported an update analysis of urine sam-
ples from 1000 participants of the
Guernsey Island cohort, including 69 con-
firmed breast cancer cases (56). No associ-
ations were evident with premenopausal
estrogens, but among women who were
postmenopausal at the time ofurine collec-
tion, there were evident trends ofincreas-
ing risk of breast cancer with increasing
excretion ofestradiol and total estrogens.
Thus, in the last 2 years, and in sharp
contrast with previous data, the hypothe-
sis that in postmenopausal women circu-
lating estrogens are associated with the
risk of breast cancer has gained unex-
pected momentum from new data, show-
ing relative risks that are sufficiently
strong to justify additional efforts to
exploit their potential preventive implica-
tions. Ifit can be shown conclusively that
endogenous estrogens are strongly related
to breast cancer risk, the road may be
open to investigate the origins ofthe asso-
ciation and to explore new possibilities for
chemopreventive, nutritional and lifestyle
interventions. Before launching new
efforts, however, thought should be given
to why the outcome of epidemiological
studies has shifted so dramatically. Because
all the recent, positive reports were the
product of case-controls nested within
prospective cohorts and the older negative
ones were hospital-based case-control
studies, it is possible that differences in
study design could explain the huge
differences in results between early and
recent studies.
Issues in Study Design
Traditional Case-ControlStudies
The majority ofearly studies that assessed
the association between endogenous estro-
gens in blood and urine and the risk of
breast cancer were case-control studies in
which breast cancer cases were identified
among patients attending medical facilities
for diagnosis or treatment. In this study
design, assessment ofexposure to endoge-
nous hormones is performed among the
cases on biological specimens (e.g., periph-
eral venous blood, urine, or salivaJ that are
obtained at the time, or sometimes long
after, breast cancer has become clinically
manifest. Because sampling occurs after the
onset of clinical disease, there is uncer-
tainty as to whether exposure truly pre-
cedes disease or, in other words, whether
exposure and disease occur in the correct
temporal sequence-one of the most
fundamental prerequisites ofobservational
studies. Thus, the results of these studies
are meaningful only ifit can be reasonably
assumed that the presence ofthe disease at
the clinical stage does not influence hor-
monal measurements and that the hor-
monal measurements provide an unbiased
and accurate reflection ofhormone levels
during an appropriate time in the natural
history ofthe disease.
It is not known whether biochemical
measurements conducted on samples
obtained after clinical diagnosis reflect long-
term endogenous hormone levels. However,
it is clear that under normal conditions,
blood hormone levels are subject to fluctua-
tions, such as circadian, menstrual, and sea-
sonal cycles, and are influenced by physical
activity, diet, emotions, trauma, and disease.
The possibility ofdistortion on relative risk
estimates consequent to the misclassification
ofexposure induced by these fluctuations
has been recognized. Attempts at reducing
their impact have been made by most inves-
tigators by restricting biological sample col-
lection to a narrow time frame, such as a
few hours ofthe day, a single season, or a
specific phase ofthe menstrual cycle (but
never by repeat sampling, which might have
been more effective).
Even ifsingle hormonal measurements
were a good reflection ofpast levels in nor-
mal conditions, postdiagnostic sampling
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can introduce bias; the disease itself may
affect hormonal concentrations among the
cases, but not among the nondiseased
controls. Clinical cancer is accompanied by
localized or systemic responses, such as
angiogenesis, necrosis, inflammatory reac-
tions in regional lymph nodes, and meta-
static spread, which may be accompanied
by (or be the expression of) metabolic or
hormonal imbalance. Furthermore, among
the patients, but not the controls, the diag-
nosis ofcancer is accompanied byinevitable
emotional distress, by changes in diet, and
by sudden reductions in the level ofphysi-
cal activity, which can have a profound
influence on hormonal concentrations in
biological fluids. Obviously, the potential
for bias will be greater in studies in which
specimen sampling is performed after the
start ofsurgical or medical treatment.
It is not surprising that the results of
case-control studies with postdiagnostic
sampling have shown inconsistent results.
Indeed, in the absence ofany information
about the validity of the underlying
assumptions concerning postdiagnostic
measurements, it could not be reasonably
excluded that the absence or the presence
of an association simply reflects measure-
ment error or bias. Therefore, the results of
these studies should be taken very cau-
tiously and with the understanding that
their value in assessing associations is
limited or at best purely exploratory.
ProspectiveCohortStudies
The alternative approach used to assess the
relationship between endogenous hormones
and breast cancer is conduction ofcase-con-
trol studies nested within a prospective
cohort. In this type ofstudy, the assessment
ofexposure is performed on biological sam-
ples collected from all or most ofthe cohort
members prior to clinical disease onset and
stored for future use (Figure 1). Rather than
measuring biochemical markers on speci-
mens from all members of the cohort,
which would be prohibitively expensive,
only breast cancer cases and controls drawn
from among the nondisease members ofthe
cohort are considered. This approach pro-
vides unbiased results and only a negligible
loss ofstatistical power, as compared to a
full cohort analysis (57,58). Samples from
the cases are collected prior to the clinical
detection of cancer so that exposure and
clinical disease follow in the appropriate
temporal sequence. In addition to being free
from postdiagnostic sampling problems,
nested case-control studies offer the unique
advantage that cases and controls are drawn
Preclinical
disease
Diagnosis Clinical
disease
Time
Specimen sampling
Figure 1. Sampling of biological specimens in case-control studies nested within a prospective cohort.
from the same source population and are
highlyinternally comparable.
Prediagnostic sampling and high
comparability between cases and controls
make case-control studies nested within
prospective cohorts the ideal study design
to assess the etiologic role ofmetabolic fac-
tors in chronic disease, particularly endoge-
nous hormones in breast cancer. Few such
studies have been conducted for logistical
and financial reasons. A large case-control
study with postdiagnostic sampling can be
completed rapidly (i.e., a few years), pre-
sents limited organizational complexities,
and is usually relatively inexpensive. A
medium-size case-control study nested
within a cohort, unless it exploits existing
resources, requires a period of time suffi-
ciently long for cases to accrue, could be
logistically complex and (because the
underlying cohort is large) usually requires
a substantial budget.
It is undeniable that cohort studies take
a long time to complete, are complex and
expensive, and carry the danger that, after
several years ofdata collection, the hypo-
theses justifying the original efforts are
superseded by new research developments,
or that the laboratory methods originally
proposed become obsolete. On the other
hand, it is true also that the long time lag
between biological sampling and the occur-
rence ofdinical disease represents the most
fundamental strength of these studies.
Unless biomarkers are developed that
would allow us to estimate past exposures
with sufficient degree ofreliability, the best
chance to study the role of endogenous
hormones in relation to cancer is by mea-
suring hormones as early as possible during
the various stages ofthe natural history of
the disease, a goal that can be achieved
only through well designed and long-lived
prospective cohort studies.
A further advantage of the nested
case-control approach over traditional hos-
pital-based case-control studies is the need
to bank biological specimens from the
whole cohort. Even though the bank is
organized to fulfill the requirements of
specific hypotheses, ultimately, only a very
small fraction of the total number of
specimens banked will be used to test the
study's original hypotheses. Most of the
remainder will be available for additional
investigations. Thus, prospective cohort
studies with biological banking provide
resources of great efficiency that would
remain available for scientific inquiries
long after the completion of the initial
study. This unique advantage, however,
must be openly recognized at the very
beginning so that the cohort and its biolog-
ical bank are designed to take full advan-
tage ofit. The design ofsuch studies should
take into account issues such as a) obtaining
appropriate informed consent from individ-
uals for future reference, b) the timing of
sampling in relation to physiological factors
(e.g., pregnancy, ovariectomy, menstrual
cycle, menopause) and external events (e.g.,
recent meals, medication use, recreational
drug use, physical activity), c) the tight stan-
dardization ofprocedures for the collection,
preparation, and handling ofbiological spec-
imens, and d) considerations for long-term
storage ofspecimens, such as storage temper-
ature, type ofspecimens in storage, volume
and number ofaliquots, defrosting, and the
likelihood ofaccidents. All these factors may
significantly affect the efficiency ofprospec-
tive cohort studies in conducting future
studies on many disease outcomes. They
may mask differences in biomarker levels
between individuals or within the same
individual at different points in time, or may
affect the ability to control for confound-
ing, or to assess effect modification (e.g.,
through markers ofgenetic susceptibility).
Future Perspectives
Emerging epidemiological evidence shows
that increased blood levels of major sex
steroid hormones (androgens and estro-
gens), play an important role in the etiol-
ogy of breast cancer in postmenopausal
women. Recent data also show that women
with the thickest bone density, which can
be taken as a surrogate for cumulative, life-
time exposure to endogenous hormones,
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experience a 3-fold increased risk ofbreast
cancer as compared to women with thin
bones (59). These findings complement
and expand the observations based on
direct measurement ofendogenous hor-
mones and are consistent with data relating
reduced risk ofbreast and endometrial can-
cers to the occurrence ofbone fractures in
the forearm (60) and hip (61,62).
Increased levels ofcirculating hormones
may be the result ofan overall increase in
ovarian or adrenal secretion occurring or
persisting after menopause. In high-risk
populations, women tend to experience
menarche at a younger age, menopause at
an older age and reach higher adult body
height and weight than in low-risk popula-
tions (63,64). These factors, which have
been associated with increased breast cancer
risk in all populations (65), suggest that the
Western lifestyle influences cancer risk early
in life. Thus, biochemical measurements of
endogenous hormones could be used as
biological markers ofmetabolic disregula-
tion induced by a lifetime exposure to the
hypercaloric diet and sedentary lifestyle that
are typical ofWestern populations. Kaaks
(66) argued that nutritionally induced
hyperinsulinemia and insulin resistance are
the fundamental metabolic changes at the
root ofthe pathologic processes leading to
breast cancer. This hypothesis offers a
model foraphysiologic linkbetweenlifetime
exposure to overnutrition, excessive body
weight and low physical activity, the devel-
opment of chronic alterations in the
endocrine secretion ofsteroid hormones,
especially ovarian androgens, and reduced
production ofSHBG by the liver. In high-
risk populations, nutritionally induced
endocrine disregulation would begin early in
life so that the key to understanding breast
cancer etiology would be in the metabolic
and hormonal alterations present in child-
hood and in pre- or peripubertal years,
whichcontinue throughout awoman's life.
A number ofobservations, including
large differences in incidence rates between
populations (67) and studies ofwomen
migrating from low-risk to high-risk areas
(68-70) suggest that diet is probably the
single most important factorin breast cancer
etiology. This may hold true even though
analytical epidemiological studies have failed
to reveal specific patterns ofnutrition that
are associated with the disease (71). The
lack ofa convincing association between
diet and breast cancer can be ascribed in
large part to methodological problems, e.g.,
the inadequacy ofdietary assessment and
the difficulty ofmeasuring small differences
among individuals living in the same geo-
graphical area who share similar nutritional
habits (72). It has been suggested (66) that
the Western lifestyle would induce hor-
monal disregulation that is dependent more
on individual susceptibility to specific physi-
ologic responses to overnutrition than on
comparatively small differences in habitual
diet, especially ifdietary assessment covered
onlyashort period oftime duringadult life.
Thus, in light ofthe limitations ofdietary
assessment, it seems that the role ofWestern
lifestyle in breast cancer would be better
understood with knowledge ofthe precise
metabolic and hormonal responses induced
byovemutrition andlackofphysical activity
rather than with the study ofdietary factors
perse.
In summary, evidence is rapidly emerg-
ing in support ofa key role for endogenous
sex hormones in breast cancer etiology.
Hormonal metabolite concentrations in
body fluids may be used as biological
markers oflong-term disregulation induced
by exposure to overnutrition and lack of
physical activity-probably the most
important risk factors for breast cancer in
all populations. Unfortunately, it took an
inordinately long time to recognize the key
role of endogenous hormones. Addi-
tionally, the etiologic relationship between
endogenous hormones and disease could
not be convincingly addressed in epidemi-
ologic studies in which hormonal measure-
ments were madewell after the disease had
surfaced clinically. In light ofthe success
of more recent efforts, we now have the
elements for an effective effort aimed at
reducing the uncertainties surrounding the
etiology ofbreast cancer.
New prospective cohort studies will
offer the advantage ofallowing the mea-
surement of metabolic and hormonal
markers in the early stages ofthe disease, or
even before the beginning of the disease
itself. These studies may elucidate the role
of the major endogenous reproductive
hormones in breast cancer and their rela-
tionship to nutritional and metabolic risk
factors. Bone density, breast density,
anthropometry, and physical activity, aswell
as genetic markers ofindividual susceptibil-
ity (which may confer increased risk
through an effect on endogenous hor-
mones or through specific physiologic and
metabolic responses to overnutrition), may
need to be considered. These studies will
focus primarily on hormonal and meta-
bolic imbalances associated with breast
cancer in adult life. However, their results
should create new opportunities to relate
metabolic biomarkers with lifestyle deter-
minants earlier in life, thus providing the
necessary knowledge to design effective
strategies for breast cancer prevention.
The new studies will not be rapid or
easy to conduct. The best investment ofour
modest resources during the next decade
would be to elucidate the role ofendoge-
nous sex hormones in breast cancer. Such
an investment of time is necessary and
unavoidable; it would be difficult, if not
impossible, to implement effective mea-
sures for the primary prevention ofbreast
cancer without a sufficient epidemiological
knowledge of nutritionally induced hor-
monal imbalances. Even though time
requirements would be substantial, this
effort would create tremendous opportuni-
ties for additional research, e.g., explo-
ration ofthe association ofbreast cancer
with exposure to xenobiotics in the envi-
ronment or in the diet, the role ofspecific
nutritional factors measurable through
biomarkers, and other types of chronic
diseases affecting women.
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